子宫内膜异位症血管形成的基本机制及其临床意义
本综述概述子宫内膜异位症血管形成的三大基本机制:血管生成、血管发生和微血管对接,并探讨其在诊断与治疗中的未来临床意义。血管生成相关生长因子和内皮祖细胞可能作为诊断与分类的生物标志物,抗血管生成化合物和血管阻断剂可能靶向病灶血管。
要点
- 子宫内膜异位症血管形成涉及血管生成、血管发生和微血管对接三种机制。
- 循环内皮祖细胞从骨髓动员并整合入病灶新生微血管内皮,称为血管发生。
- 血管生成生长因子和内皮祖细胞可能作为诊断与分类的生物标志物。
核心结论
- 子宫内膜异位症血管形成涉及血管生成、血管发生和微血管对接三种机制,为新型诊断和治疗方法的建立提供了不同可能。
研究设计与样本
- 综述类:在PubMed检索英文文献,关键词包括「endometriosis」「endometriotic lesions」「angiogenesis」「vascularization」「vasculogenesis」「endothelial progenitor cells」「inosculation」,纳入动物和人类研究,发表时间不限。
主要发现
- 子宫内膜异位病灶的植入通常伴随血管生成,即从已存在血管形成新血管。
- 循环内皮祖细胞(EPCs)从骨髓动员并招募至病灶,整合入新生微血管内皮,称为血管发生。
- 脱落子宫内膜碎片中预形成的微血管与周围宿主微血管对接,使异位组织快速获得血供。
- 血管生成生长因子和EPCs可能作为诊断与分类的生物标志物。
- 病灶内血管形成和成熟微血管可能成为抗血管生成化合物和血管阻断剂的靶点。
关键数值与推荐
- 综述汇总:血管生成受血管生成生长因子和激素的复杂调控,激活细胞内通路及相关信号分子。
- 综述汇总:血管生成生长因子和EPCs可能作为诊断与分类的生物标志物。
- 综述汇总:抗血管生成化合物和血管阻断剂可能靶向病灶血管形成和成熟微血管。
临床怎么用
- 原文未据此给出推荐。
局限性
- 在子宫内膜异位症管理中建立基于血管形成的策略仍是一大挑战。
- 诊断方面,必须鉴定出具有高灵敏度和特异性的可靠血管生成和血管发生生物标志物组合。
- 治疗方面,需要选择性靶向病灶血管形成且不引起严重副作用的新型化合物。
- 近期进展提示这些目标可能在不久的将来实现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vascularization is a major hallmark in the pathogenesis of endometriosis. An increasing number of studies suggests that multiple mechanisms contribute to the vascularization of endometriotic lesions, including angiogenesis, vasculogenesis and inosculation. OBJECTIVE AND RATIONALE: In this review, we provide an overview of the basic mechanisms of vascularization in endometriosis and give special emphasis on their future clinical implications in the diagnosis and therapy of the disease. SEARCH METHODS: Literature searches were performed in PubMed for English articles with the key words 'endometriosis', 'endometriotic lesions', 'angiogenesis', 'vascularization', 'vasculogenesis', 'endothelial progenitor cells' and 'inosculation'. The searches included both animal and human studies. No restriction was set for the publication date. OUTCOMES: The engraftment of endometriotic lesions is typically associated with angiogenesis, i.e. the formation of new blood vessels from pre-existing ones. This angiogenic process underlies the complex regulation by angiogenic growth factors and hormones, which activate intracellular pathways and associated signaling molecules. In addition, circulating endothelial progenitor cells (EPCs) are mobilized from the bone marrow and recruited into endometriotic lesions, where they are incorporated into the endothelium of newly developing microvessels, referred to as vasculogenesis. Finally, preformed microvessels in shed endometrial fragments inosculate with the surrounding host microvasculature, resulting in a rapid blood supply to the ectopic tissue. These vascularization modes offer different possibilities for the establishment of novel diagnostic and therapeutic approaches. Angiogenic growth factors and EPCs may serve as biomarkers for the diagnosis and classification of endometriosis. Blood vessel formation and mature microvessels in endometriotic lesions may be targeted by means of anti-angiogenic compounds and vascular-disrupting agents. WIDER IMPLICATIONS: The establishment of vascularization-based approaches in the management of endometriosis still represents a major challenge. For diagnostic purposes, reliable angiogenic and vasculogenic biomarker panels exhibiting a high sensitivity and specificity must be identified. For therapeutic purposes, novel compounds selectively targeting the vascularization of endometriotic lesions without inducing severe side effects are required. Recent progress in the field of endometriosis research indicates that these goals may be achieved in the near future.
引用
- Laschke MW, Menger MD. Basic mechanisms of vascularization in endometriosis and their clinical implications. Hum Reprod Update. 2018. PMID: 29377994. doi:10.1093/humupd/dmy001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。